REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – Two analyses of data from the phase III FREEDOMS trial report that fingolimod increases the proportion of  MS patients who are disease-free and reduces brain atrophy compared to placebo.